Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Glenn Dranoff"'
Autor:
Tomas Rejtar, Markus Vogel, Srinivas Chakravarthy, Joseph Anthony D'alessio, Katie Russo, Alyssa Grantham, David A. Ruddy, Sabine Deutsch, Si-Qi Liu, Katherine Seiss, Tiancen Hu, William R. Tschantz, Glenn Dranoff, Casey Landry, Rajiv Chopra, Joel Wagner, Brian Granda, Kimberly Aardalen
Publikováno v:
Cancer Immunol Res
CD3-bispecific antibodies represent an important therapeutic strategy in oncology. These molecules work by redirecting cytotoxic T cells to antigen-bearing tumor cells. Although CD3-bispecific antibodies have been developed for several clinical indic
Autor:
Jingjing Li, George F. Murphy, Margaret A. Shipp, David F. McDermott, Anita Giobbie-Hurder, Xiaoyun Liao, Glenn Dranoff, Matthias Piesche, Scott J. Rodig, Jing Ouyang, Erin M. Connolly, Xinqi Wu, F. Stephen Hodi, Donald P. Lawrence, Jun Zhou
Publikováno v:
Cancer Immunology Research. 5:446-454
The combination of anti-VEGF blockade (bevacizumab) with immune checkpoint anti–CTLA-4 blockade (ipilimumab) in a phase I study showed tumor endothelial activation and immune cell infiltration that were associated with favorable clinical outcomes i
Publikováno v:
Cancer Immunology Research. 4:95-100
We demonstrate that a poly(lactide-co-glycolide) (PLG) cancer vaccine can be used in combination with immune checkpoint antibodies, anti–CTLA-4 or anti–PD-1, to enhance cytotoxic T-cell (CTL) activity and induce the regression of solid B16 tumors
Autor:
Yvonne Y. Li, Grit S. Herter-Sprie, Daniel B. Costa, Scott J. Rodig, Jeffrey A. Engelman, Amanda J. Redig, Esra A. Akbay, Kwok-Kin Wong, Shohei Koyama, Leena Gandhi, Kevin A. Buczkowski, Bruce E. Johnson, Peter S. Hammerman, Glenn Dranoff, Sidharta P. Gangadharan, William G. Richards, Sangeetha Palakurthi, Peter E. Fecci, F. Stephen Hodi, Gordon J. Freeman, Hajime Asahina, Meghana M. Kulkarni, Mari Kuraguchi, Pasi A. Jänne, Raphael Bueno, Robert E. Jones
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-9 (2016)
Nature Communications
Nature Communications
Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed. In this study, to elucidat
Autor:
K. G. Papavinasasundaram, Alissa C. Rothchild, Cláudio Nunes-Alves, Xinchun Chen, Girija Goyal, Qianting Yang, Christopher M. Sassetti, Samuel M. Behar, Jinhee Lee, Britni L. Stowell, Glenn Dranoff
Publikováno v:
mBio
mBio, Vol 8, Iss 5 (2017)
mBio, Vol 8, Iss 5, p e01514-17 (2017)
mBio, Vol 8, Iss 5 (2017)
mBio, Vol 8, Iss 5, p e01514-17 (2017)
Mice deficient for granulocyte-macrophage colony-stimulating factor (GM-CSF−/−) are highly susceptible to infection with Mycobacterium tuberculosis, and clinical data have shown that anti-GM-CSF neutralizing antibodies can lead to increased susce
Autor:
Robert J. Soiffer, Haesook T. Kim, Joseph H. Antin, Michael Nehil, P Altevogt, Corey Cutler, Yukoh Nakazaki, Glenn Dranoff, Jerome Ritz, Jeremy Weiser, Vincent T. Ho, Dmitriy Kolodin, Edwin P. Alyea, Matthias Piesche, John Koreth, Christine Canning, Nasser K. Yaghi, Helena Kiefel
Publikováno v:
Piesche, M, Ho, V T, Kim, H, Nakazaki, Y, Nehil, M, Yaghi, N K, Kolodin, D, Weiser, J, Altevogt, P, Kiefel, H, Alyea, E P, Antin, J H, Cutler, C, Koreth, J, Canning, C, Ritz, J, Soiffer, R J & Dranoff, G 2015, ' Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions ', Clinical Cancer Research, vol. 21, no. 5, pp. 1010-8 . https://doi.org/10.1158/1078-0432.CCR-14-1956
Purpose: The graft-versus-leukemia (GVL) reaction is an important example of immune-mediated tumor destruction. A coordinated humoral and cellular response accomplishes leukemia cell killing, but the specific targets remain largely uncharacterized. T
Autor:
Kai W. Wucherpfennig, Rong En Tay, Lucas Ferrari de Andrade, Bettina Franz, Christopher Harvey, Kenneth F. May, Guo-Cheng Yuan, Soumya Badrinath, Jason Pyrdol, Adrienne M. Luoma, Sebastian Kobold, Daphne Tsoucas, Charles H. Yoon, Deng Pan, F. Stephen Hodi, Yoshinaga Ito, Glenn Dranoff
Publikováno v:
Science (New York, N.Y.). 359(6383)
Helping NK cells find their way MICA and MICB proteins can be expressed on tumors and act as “kill me” signals to the immune system. But tumors often disguise themselves by shedding these proteins, which prevents specialized natural killer (NK) c
Autor:
Byron Hua Kwan, Richard O. Hynes, Noor Momin, Botong Ma, Naveen K. Mehta, Ahmed A. Eltahir, Harun R. Sugito, Alessandro Angelini, Alice Tzeng, Jennifer R. Cochran, Mary K. Delaney, K. Dane Wittrup, Monique J. Kauke, Alecia M. Maragh, Eric F. Zhu, Glenn Dranoff, Patrick A. Murphy
Publikováno v:
The Journal of Experimental Medicine
Integrin targeting for cancer has primarily focused on antagonizing integrin function, which has been clinically ineffective to date. In this study, Kwan et al. repurpose integrins as a beacon for recruiting immune effector functions to bolster curre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fa3fadf7a75f648392a032bdc6e24d3
http://hdl.handle.net/10278/3691745
http://hdl.handle.net/10278/3691745
Autor:
Seth Ettenberg, Nicholas S. Wilson, Sarah M. Rue, Maurice Windman, Yannick Bulliard, Jennifer Brogdon, Glenn Dranoff, Rose Jolicoeur, Deborah A. Knee
Publikováno v:
The Journal of Experimental Medicine
Antibodies that coengage activating FcγRs expressed by tumor-associated leukocytes facilitate the selective elimination of intratumoral T cells.
Fc γ receptor (FcγR) coengagement can facilitate antibody-mediated receptor activation in target
Fc γ receptor (FcγR) coengagement can facilitate antibody-mediated receptor activation in target
Autor:
Mark M. Awad, Amir Reza Aref, Ignacio I. Wistuba, Tran C. Thai, Edwin Parra-Cuentas, Ferdinandos Skoulidis, Jing Wang, John V. Heymach, Hajime Asahina, Warren Denning, Esra A. Akbay, Jillian D. Cavanaugh, Matthew D. Hellmann, Margaret Soucheray, Kevin A. Buczkowski, Abigail Altabef, Peng Gao, Glenn Dranoff, F. Stephen Hodi, David A. Barbie, Peter S. Hammerman, Shunsuke Kitajima, Grit S. Herter-Sprie, Peter E. Fecci, Takeshi Shimamura, Gordon J. Freeman, Yvonne Y. Li, Kevin Rhee, Yan Liu, Haikuo Zhang, Lixia Diao, Kwok-Kin Wong, Shohei Koyama
Publikováno v:
Cancer research, vol 76, iss 5
STK11/LKB1 is among the most commonly inactivated tumor suppressors in non–small cell lung cancer (NSCLC), especially in tumors harboring KRAS mutations. Many oncogenes promote immune escape, undermining the effectiveness of immunotherapies, but it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b2315ba8b0aaf613f839230766f8586
https://escholarship.org/uc/item/37r0490t
https://escholarship.org/uc/item/37r0490t